References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2016-19-21-27

medsovet-1623

Research Article

КАРДИОЛОГИЯ

CARDIOLOGY

ОПТИМАЛЬНЫЙ ВЫБОР КОМБИНАЦИИ ПРЕПАРАТОВ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ ФОКУС НА СОЧЕТАНИЕ ИНГИБИТОРА АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА И АНТАГОНИСТА КАЛЬЦИЯ

OPTIMAL CHOICE OF THE DRUG COMBINATION IN ARTERIAL HYPERTENSION THERAPY. FOCUS AT COMBINATION OF ANTIOTENSIN-CONVERTING ENZYME AND CALCIUM ANTAGONIST COMBINATION

ДЖАИАНИ

Н. А.

DJAIANI

N. A.

д.м.н., профессор

MD, Prof.

Московский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияEvdokimov Moscow State Medical Stomatologic UniversityRussian Federation

2016

30122016

0192127

2016

ДЖАИАНИ Н.А.

DJAIANI N.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/1623

Сердечно-сосудистые заболевания (ССЗ) в настоящее время являются актуальной проблемой как национальной, так и мировой практики. Ведущее место среди них принадлежит артериальной гипертонии (АГ) ввиду того, что последняя приобрела характер эпидемии. Медико-социальная значимость АГ обусловлена тем, что данная патология является важнейшим фактором риска основных ССЗ – инфаркта миокарда и мозгового инсульта, определяющих высокую смертность [1].

Currently cardiovascular diseases (CVD) are an urgent problem of national and international practice. The arterial hypertension takes the leading place due to the fact that the disease has acquired the character of epidemics. The medical and social importance of AH is preconditioned by the fact that this pathology is an important risk factors of major CVD – myocardium infarction and brain stroke that predetermine the high mortality rates [1].

сердечно-сосудистые заболеванияартериальная гипертонияцелевое артериальное давление

cardiovascular diseasesarterial hypertensiontarget arterial pressure

References1

Шальнова С., Кукушкин С., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии. Врач, 2009, 12: 39-42.

Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Кардиологический вестник, 2015, Х(1): 3-30.

2013 ESH/ESC Guidelines for themanagement of arterial hypertension. The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension, 2013, 31(7): 1281-1357.

Opie LH, Messerly FH, Combination Drug Therapy for Hypertension. 1997. Lippincott-Raven Publishers. Philadelphia New Yorc. P. 176.

Шабалин А.В. Комбинированная антигипертензивная терапия: состояние, достижения. 2001. Новосибирск. С. 96.

Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. 2007. М., Mеdia Medica. С.183.

Маколкин В.И. Комбинация ингибитора ангио тензинпревращающего фермента и антагониста кальция высоко эффективна. РМЖ, 2009, 8: 534-539.

Остроумова О.Д., Смолярчук Е.А., Хворостяная И.В. Новые подходы к лечению артериальной гипертонии: от выбора оптимального препарата к выбору оптимальной комбинации. РФК, 2010, 6(5): 709-716.

The Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensinconvertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med, 2000, 342: 14Б-1БЗ.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int, 2004, 65: 2309-2320.

Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Randomised placebo- controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet, 1997, 349: 1857- 1863.

Lewis EJ et al. Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001, 20(345) 12: 851- 60.

Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, 366: 895-906.

Kjeldsen SE, Jamerson KA, Bakris GL et al. Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension Investigators. Predictors of blood pressure response to intensified and fixed combination treatment of hypertentsion: the ACCOMPLISH study. Blood Press, 2008, 17(1): 7-17.

Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet, 2010 April 3, 375(9721): 1173-81.

Pepine CJ., Handberg-Thurmond E. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet0based randomized trial in coronary artery disease patients with hypertension. JACC, 1998, 32: 1228-37.

Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin- convertingenzyme inhibitors and diuretics for hypertensionin the elderly. N Engl J Med, 2003, 348(7): 583-92.

The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. NEJM, 1991, 325: 293-302.

Vermes E, Tardif JC, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation, 2003, 107(9): 1291-6.

Vermes E, Tardif JC, Bourassa MG et al. Enalapril reduces the incidence of atrial fibrillation in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation, 2003, 107(9): 2926-31.

The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study. NEJM, 1991, 316: 1429-1435.

Borghi С, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer Adherence, 2012, 6: 449-455.

Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med, 1998, 128: 982-988.

Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of Mild Hypertension Study (TOMHS) final results. J Am Med Assoc, 1993, 270: 713-24.

Borghi С, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer Adherence, 2012, 6: 449-455.

Sabbatini M, Leonardi A, Testa R et al. Effect of Calcium Antagonists on Glomerular Arterioles in Spontaneously Hypertensive Rats. Hypertension, 2000, 35: 775-779.

Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab, 2004, 17(5): 259-66.

Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA study. Ren Fail, 2005, 27(1): 73-80.

Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with rennin-angiotensin axis-blocking drugs. Ren Fail, 2010, 32: 192-197.

Angelico P, Guarneri L, Leonardi A et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharmacol, 1999, 51: 709-714.

Ortiz M, Calcino G. Inferred Mortality Differences between Dihydropyridine Antihypertensives. Hypertension, 2009, 53: 1116.

Borghi C, Prandin MG, Dormi A. The use of lercanidipine can improve the individual tolerability to dihydropyridine calcium blockers in hypertensive patients [abstract]. J Hypertens, 2000, 18(Suppl 2): S155.

Cafiero M, Giasi M. Long-term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension. J Cardiovasc Pharmacol, 1997, 29(Suppl 2): 45-49.

Marx A, Lichtenthal A, Milbredt C et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. J Hypertens, 2004, 22(Suppl 2): S236.

Lund-Johansen P, Stranden E, Helberg S et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens, 2003, 21: 1003-1010.

Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract No. P1.191]. J Hypertens, 2000, 18(Suppl. 2): S65.

Sanchez A, Sayans R, Alvarez JL et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract no. 12]. Fourth European Meeting on Calcium Antagonists, 1999, Oct 27–29, Amsterdam.

Барышникова Г.А., Чорбинская С.А., Степанова И.И. Дигидропиридиновые антагонисты кальция в лечении артериальной гипертонии у женщин: фокус на лерканидипин. Трудный пациент, 2013, 11(11): 10-16.

Bang L, Chapman T, Goa K. Lercanidipine – a review of its efficacy in management of hypertension. Drugs, 2003, 22: 2449-2472.

Небиеридзе Д.В. Антагонисты кальция в клинической практике: фокус на метаболические и сосудистые эффекты. РФК, 2007, 3(2): 67-71.

Lithell H. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care, 1991, 14: 203-209.

Berne C: Metabolic effects of ACE inhibitors. J Int Med, 1991, 229 (suppl 2): 119-125.

Quarti F, Seravalle G, Dell Oro R et al. Effects of lercanidipine/enelapril combination on neurometabolic alterations in obese hypertensive subjects with High blood pressure. Cardiovasc Prev, 2010, 17(3): 1120.

Scholze J, Bramlage P, Trenkwalder P, Kreutz R. Efficacy and safety of a fixed- dosecombination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother, 2011, 12(17): 1- 9.

Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung, 2010, 60: 124-30.

Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens, 2006, 24: 185-92.

Puig JG, Calvo C, Luurila O et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo- controlled, randomized, crossover study with four ABPM. J Hum Hypertens, 2007, 21: 917-24.

The authors declare that there are no conflicts of interest present.